Biotechnology · Malvern, Pennsylvania, United States
$1.99
-0.50% (-$0.01)2026-07-08
Smart-Money SignalNeutral · 52/100— Insiders are net buyers over 90 days ($143K, 3 buys vs 0 sales)
Revenue$0
Net Income-$17.6M
EPS$-0.63
Market Cap$56.8M
Price Performance
Historical data including institutional events
Company Profile
M
Maria Maccecchini
CEO & Executive Director
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
The companyâs lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimerâs disease, as well as in phase 3 to treat parkinsonâs disease; and is in phase 2 clinical trial to treat lewy body dementia.
It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimerâs disease and dementia.
Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
